All News
Racial disparities in Bilateral Knee Arthroplasty in Osteoarthritis
Although arthritis-related activity, disabling work limitations, and severe pain (which are indications for TKA) disproportionately impact African American patients compared to White patients, there are marked racial disparities documented in utilization and complications in unilateral total knee arthroplasty.
Read Article
IVIg in Dermatomyositis: Dr. Sheila Reyes ( @RHEUMarampa) reviews abstract #0995 presented at #ACR20.
https://t.co/PKYATqUh0d
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @KDAO2011 : Very strong push by #ACR20 to recc MTX in most RA patient scenarios including RA ILD, RA nodules, NAFLD in new RA guidance document @rheumnow
Dr. John Cush RheumNow ( View Tweet)
Citrulline Reactive B Cells Present in Lungs of Risk, Early RA: Richard Conway ( @RichardPAConway) discusses ACR abstract #1445 presented #ACR20
https://t.co/WjcBPay86P https://t.co/JnUVss0FDK
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @DrMiniDey : Patient-physician discordance seen in ~30% RA patients starting #DMARDs
- ↑Patient-reported pain; functional impairment assoc. w/ discordance
- Patient-centric treatment discussions needed to reduce discordance
Abs#1978
https://t.co/uTJehn5Qs5 https://t.co/289d3VsE22
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @doctorRBC : Upadacitinib vs. Adalimumab vs. PBO in PsA
Phase 3 RCT
⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA
*⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior
*⃣Similar VTE in all arms
#ACR20 Abs#2026 https://t.co/n5wcKK1juC
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Does IL-6 blockade prevent mechanical ventilation or death in #COVID19? MGH study by Dr. Stone Abst#L07 graph shows no benefit #ACR20 https://t.co/JWa1LSIC8R https://t.co/EOEoHhmKqk
Dr. John Cush RheumNow ( View Tweet)
RA Risk Factors and Early RA: Dr. Jeffrey Sparks ( @jeffsparks) and Dr. Janet Pope ( @Janetbirdope) #ACR20
https://t.co/vN7Dt60R4W https://t.co/K5vAhEQfks
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Kay leads an internat'l panel of rheums to elicit their opinions on key abstracts at #ACR20.
Panelists: Dr. David Liew, Dr. Eric Dein, Dr. Meral El Ramahi, Dr. Richard Conway, Dr. Sheila Reyes and Dr. Jeffrey Sparks.
https://t.co/Jg6QiswnnJ https://t.co/UAqiN3F734
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/EUXQqy3VuI
Dr. John Cush RheumNow ( View Tweet)
Timely video on COVID 19 and Rheumatic Disease with Dr. Jeffrey Sparks ( @jeffsparks) #acr20
https://t.co/5Qg3HRkQyW
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @RichardPAConway :Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovas. events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat
Dr. John Cush RheumNow ( View Tweet)
Dr. Rachel Tate ( @uptoTate) reviews outpatient billing and coding pearls presented at a session at the #ACR20 meeting.
https://t.co/66YbqXcncr https://t.co/PDdVKfNJYd
Links:
Dr. John Cush RheumNow ( View Tweet)
Check on Pneumococcal Vaccination: Dr. Janet Pope ( @Janetbirdope) #ACR20
https://t.co/D9EQ3Tl2Ot https://t.co/Zn8IVorCcs
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @CreakyJoints : .@LCalabreseDO from @ClevelandClinic is discussing the science of #empathy in #rheumatology at #ACR20.
How important is empathy in your doctor-patient relationship? https://t.co/dnJ3f8QouE
Dr. John Cush RheumNow ( View Tweet)
Revisit our #ACR20 coverage. Listen to our Day 3 part II recap. Follow the link below or find us on Apple/Android podcasts.
https://t.co/1TcXfU5TMg https://t.co/hn298mJIUL
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @SattuiSEMD :L06: Mavrilimumab in #GCA
Efficacy+safety of MAV maintaining sustained remission 26w new and relapsing/ref #GCA
Flare risk ➡️ 62% risk ⬇️ of flare w/ MAV
Sustained remission➡️ 33% ⬆️ in MAV
No diff in new/relapsing/ref pts, No diff in AE
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
"RT @DrMiniDey : RITAZAREM trial long-term f/u
-RTX vs AZA after RTX-induced remission in ANCA
-RTX superior to AZA to prevent relapse
-Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period
Abs#2052
https://t.co/cKV7qM77og
Links:
Dr. John Cush RheumNow ( View Tweet)
Fibromyalgia Therapies Show Limited Evidence of Pain and QOL Reduction
https://t.co/jpZC4KFygJ https://t.co/k7WFNQg9AY
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Dr. Khanna NOVESA study #ACR20 Abst#L09. Autotaxin inhibitor ZIRI in early dcSSc. 21 pts ziri vs 12 PBO. mRSS at Wk24 mean difference -2.8. Ziri well-tolerated. Would be great for new drug for early SSc skin. @RheumNow. https://t.co/TOS9fp4gGK https://t.co/4SDisedzs3
Links:
Dr. John Cush RheumNow ( View Tweet)